Liver fibrosis is the final pathway stage of most chronic liver diseases, and is the main reason for
increased mortality in affected patients. Hence, this study was undertaken to evaluate the
hepatoprotective effect and the efficacies of resveratrol against thioacetamide (TAA) induced liver
fibrosis in rats. The experimental model of liver fibrosis in rats was induced by intraperitoneal (i.p)
injection of TAA at a dose (200mg/Kg b.wt / thrice / week) for 6 weeks. A total of fifty five male
rats were used in this study. All rats were divided into four groups. Group I: (Control normal
group) rats received no drugs. Group II: (TAA- group). Group III: (TAA + resveratrol protected
group) rats injected with TAA and administered resveratrol (0.5 mg/Kg body weight / day,
intraperitoneally) from the 7^th week to 12^th week. Group IV: (TAA + resveratrol treated group) rats
firstly injected with TAA from the 1^st week to 6^th week and treated daily with resveratrol (0.5
mg/Kg body weight, intraperitoneally) from the 7^th week to 12^th week. Blood samples and liver
tissue were taken and processed directly for some biochemical parameters determination. The
obtained results revealed that, a significant increase in serum ALT, AST and ALP activities, IL-6,
TGF-β1 and liver L-MDA concentrations were observed in TAA injected rats. However,
administration of resveratrol to TAA induced liver fibrosis in rats exhibited a significant decreased
in all mentioned parameters and attenuated the increased L-MDA concentration in liver tissues. On
the other hand, a significant decrease in liver antioxidant enzymes (SOD and CAT) activities were
observed in TAA injected rats when compared with control normal group. Meanwhile, resveratrol
administration resulted in a significant increase in liver SOD and CAT activities. It could be
concluded that, inhibition of lipid peroxidation, inflammation and oxidative stress and enhanced
antioxidant enzymatic status in rats liver by resveratrol suggest the potential efficiency of
resveratrol as a natural hepatoprotective and anti-inflammatory agent in treatment of liver fibrosis.